discontinuing glp-1 ISPOR 2025: Exploring reasons for discontinuation Proportion of Patients Who Discontinued

doi: 10.1016/j.neuropharm.2018.11.002 160 KongJWanLWangYZhangHZhangW

Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy

GLP-1R agonists effects on cardiovascular events The first pieces of evidence of the potential clinical benefit of GLP-1 agonists have emerged recently, pointing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, and revascularization procedures

Always keep your confirmation email and tracking number handy, and allow extra time for delivery during high-demand seasons or promotional periods

British Journal of Pharmacology , 179 (4), 625-641

Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway